Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00366002
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2006-08-17
Brief Title:
Patients Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-Week Open-Label Non-Randomized Multicenter Study to Evaluate the Patients Perception of Outcome After Treatment With Darifenacin in Overactive Bladder OAB Patients Dissatisfied With Prior Anticholinergic Therapy
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate safety efficacy and patients perception of outcome after treatment with darifenacin 75 mg once daily od with voluntary increase up to 15 mg od in patients with OAB who are dissatisfied with prior oxybutynin extended release ER or tolterodine extended release ER therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None